In short
Diagnosing Castleman disease requires careful detective work by doctors, combining physical examination, imaging studies, blood tests, and most importantly, a lymph node biopsy to confirm this rare immune disorder that causes enlarged lymph nodes and widespread inflammation.
Key points
- A lymph node biopsy examined under a microscope is absolutely essential for diagnosing Castleman disease—no other test can replace it
- Determining whether you have unicentric or multicentric disease requires imaging studies that show how many regions of your body are affected, and this distinction is critical because treatments differ dramatically
- Testing the biopsied lymph node for HHV-8 virus tells doctors which subtype of multicentric disease you have and guides them to the right treatment approach
- Blood tests revealing elevated inflammatory markers, anemia, or abnormal protein levels support a Castleman disease diagnosis but cannot confirm it alone
- Doctors must systematically rule out other conditions including lymphomas, autoimmune diseases, and infections before confirming Castleman disease because these conditions can look remarkably similar
- PET scans not only help diagnose the disease by showing active areas of inflammation but can also monitor whether treatment is working over time
- The diagnostic journey can feel frustratingly long, but thoroughness is essential because accurate diagnosis determines which treatment will save your life
- Clinical trials for Castleman disease require additional standardized testing beyond routine diagnostics to confirm eligibility and establish baseline measurements for research purposes
Introduction: Who Should Seek Diagnostics and When
If you notice swollen lymph nodes that don't go away, especially in multiple areas of your body, or if you're experiencing persistent fever, unexplained weight loss, night sweats, and ongoing fatigue, it's time to see a doctor. These symptoms could point to Castleman disease, though they can also indicate many other conditions. That's why proper testing is essential.
People with unicentric Castleman disease, where only one lymph node or one region of lymph nodes is affected, often don't have noticeable symptoms at all. The enlarged lymph node might be discovered by accident during an imaging test for something else entirely. However, sometimes that single enlarged node can press against nearby organs and cause discomfort or other problems, which would prompt you to seek medical attention.
Multicentric Castleman disease, which affects lymph nodes in several regions of the body, is more likely to cause symptoms that you can't ignore. Beyond swollen lymph nodes in multiple areas, you might experience flu-like symptoms that don't resolve, swelling in your feet or abdomen, or numbness in your hands and feet. Some people develop an enlarged spleen or liver that a doctor can feel during examination. These symptoms happen because your immune system stays activated when it should calm down, creating ongoing inflammation that affects your whole body.
It's important to understand that diagnosing Castleman disease can be challenging. The disease is rare, with only about 4,300 to 5,200 new cases diagnosed in the United States each year. Many doctors may never have seen a case. Additionally, the symptoms mimic those of other conditions, including various cancers and autoimmune diseases. This means you'll need thorough testing to rule out other possibilities and confirm whether Castleman disease is the actual problem.
Classic Diagnostic Methods
Physical Examination and Medical History
Your doctor will start by taking a detailed medical history and performing a physical examination. During the physical exam, they will feel for enlarged lymph nodes in your neck, underarms, groin, and other areas. They'll also check whether your spleen or liver feels enlarged, which can happen in multicentric Castleman disease. The doctor will ask about symptoms like fever, fatigue, night sweats, weight loss, and how long you've had them.
Blood and Urine Tests
Blood tests play a crucial role in diagnosing Castleman disease and understanding its impact on your body. These laboratory tests help rule out other infections or diseases while also detecting abnormalities typical of Castleman disease. Your blood work might reveal anemia, which is a low red blood cell count that can explain fatigue. The tests can also detect changes in blood proteins, particularly elevated levels of inflammatory markers.
In multicentric Castleman disease, blood tests often show elevated levels of a protein called interleukin-6 (IL-6), which is an inflammatory messenger that the immune system produces. High IL-6 levels contribute to many of the symptoms patients experience. Your blood might also show abnormalities in platelet counts—sometimes too low (thrombocytopenia) and sometimes too high (thrombocytosis), depending on the subtype of disease you have.
Urine tests can be performed to check for protein in the urine or other abnormalities that might suggest kidney involvement, which can occur in more severe forms of the disease.
Imaging Tests
Imaging studies are essential for seeing where enlarged lymph nodes are located and how many regions of your body are affected. This information helps doctors determine whether you have unicentric or multicentric Castleman disease, which is critical because treatment differs dramatically between these two types.
A CT scan (computed tomography scan) of your neck, chest, abdomen, and pelvis is commonly used. This detailed imaging test can find enlarged lymph nodes throughout your body, even ones you can't feel. It can also show whether your liver or spleen is enlarged. The CT scan creates detailed cross-sectional images of your body, allowing doctors to see exactly where problems lie.
A PET scan (positron emission tomography scan) might also be recommended. This test is particularly useful because it doesn't just show structure—it shows activity. PET scans can identify areas where cells are unusually active, which happens in Castleman disease. Doctors can also use PET scans later to see whether treatment is working.
Other imaging tests that might be used include chest X-rays if doctors suspect lymph nodes in your chest are affected, or ultrasound to examine specific areas more closely.
Lymph Node Biopsy: The Essential Test
The lymph node biopsy is the single most important test for diagnosing Castleman disease. Without it, a definitive diagnosis simply cannot be made. This test involves removing a tissue sample from an enlarged lymph node so it can be examined under a microscope by a pathologist—a doctor who specializes in analyzing tissue samples.
During a biopsy, a surgeon removes either part of a lymph node (called an incisional biopsy) or an entire lymph node (called an excisional biopsy). The tissue is then sent to a laboratory where the pathologist looks for specific changes in the lymph node structure that are characteristic of Castleman disease. These changes include patterns in how the cells are arranged and what types of cells are present.
The pathologist will also perform a test called immunohistochemistry to check whether the tissue is infected with human herpesvirus-8 (HHV-8). This matters enormously because if HHV-8 is present, you have HHV-8-associated multicentric Castleman disease, which requires different treatment than other forms. If the virus is not found, and you have multiple regions of enlarged lymph nodes, you would be diagnosed with idiopathic multicentric Castleman disease, meaning the cause is unknown.
It's crucial to understand that while certain lymph node features are required for a Castleman disease diagnosis, finding these features alone isn't enough. Many other diseases can cause similar changes in lymph nodes, including various lymphomas, autoimmune diseases, and infections. This is why your doctor must carefully rule out these other conditions before confirming Castleman disease.
Tests to Rule Out Other Conditions
Because Castleman disease can mimic many other diseases, your doctor will order tests to exclude other possibilities. These might include tests for HIV infection, since HHV-8-associated Castleman disease is more common in people who are HIV-positive. Tests for autoimmune diseases like lupus or rheumatoid arthritis might be necessary, as these conditions can also cause enlarged lymph nodes and inflammatory symptoms.
Your doctor may also order tests to check for lymphomas, which are cancers of the lymphatic system. The tissue from your lymph node biopsy will be carefully examined to ensure it's not lymphoma or another type of cancer. Additional blood tests might look for specific antibodies or proteins associated with other conditions.
Diagnostic Criteria for Idiopathic Multicentric Castleman Disease
For idiopathic multicentric Castleman disease specifically, doctors follow evidence-based diagnostic criteria that were established to standardize diagnosis across different medical centers. To meet these criteria, you must have enlarged lymph nodes in multiple regions of your body. The biopsy must show changes consistent with Castleman disease and be negative for HHV-8 infection.
You must also have at least two additional minor criteria, which can include clinical symptoms like fever, night sweats, or fluid accumulation, along with laboratory abnormalities like anemia, low albumin levels (a protein in blood), elevated inflammatory markers, or abnormal kidney function. Finally, all other diseases that could cause similar symptoms and test results must be excluded. This systematic approach helps ensure that patients are correctly diagnosed.
Diagnostics for Clinical Trial Qualification
When patients with Castleman disease are being considered for enrollment in clinical trials testing new treatments, they typically need to undergo additional standardized testing. These tests serve two purposes: first, to confirm they meet the specific inclusion criteria for the trial, and second, to establish baseline measurements that researchers can use to determine whether the experimental treatment is working.
Clinical trials for Castleman disease usually require participants to have their diagnosis confirmed according to standardized diagnostic criteria. This means having documentation of a lymph node biopsy showing characteristic features of Castleman disease, along with confirmation of the specific subtype—whether unicentric, HHV-8-associated multicentric, or idiopathic multicentric disease.
Baseline blood tests are typically more extensive in clinical trials than in routine clinical care. Researchers measure specific inflammatory markers, including interleukin-6 levels, C-reactive protein, and other proteins associated with inflammation. They also establish baseline measurements of blood cell counts, kidney function tests, liver function tests, and protein levels. These measurements will be repeated during and after treatment to assess the drug's effectiveness.
Imaging studies, particularly PET scans and CT scans, are often required at the start of a clinical trial to document the extent of lymph node involvement and to measure the size of enlarged nodes. These same imaging tests will be repeated at specific intervals during the trial to see whether the lymph nodes are shrinking in response to treatment.
For trials testing treatments for idiopathic multicentric Castleman disease, participants must have documentation that HHV-8 testing was negative, since HHV-8-associated disease is treated differently. They may also need to show that they meet criteria for active disease, meaning they have current symptoms and laboratory abnormalities, not just enlarged lymph nodes.
Some clinical trials may require additional specialized testing beyond standard diagnostics. This could include genetic testing of blood or tissue samples, measurements of specific immune cells, or tests for particular biomarkers that researchers believe might predict treatment response. Participants in clinical trials should expect to have more frequent blood draws and imaging studies than they would with standard treatment.
The eligibility criteria for clinical trials typically exclude patients with certain other medical conditions that could interfere with the study results or put the patient at increased risk. This means that in addition to tests confirming Castleman disease, potential participants often undergo screening tests to rule out active infections, significant heart or lung disease, or other conditions specified in the trial protocol.
Prognosis and Survival Rate
Prognosis
The outlook for people with Castleman disease varies dramatically depending on which type they have. People with unicentric Castleman disease generally have an excellent prognosis. Once the affected lymph node or nodes are surgically removed, patients are usually considered cured, and their life expectancy is typically not affected. However, there is a small risk of developing a rare and potentially deadly autoimmune condition called paraneoplastic pemphigus, which occurs in less than 5% of unicentric Castleman disease patients.
The prognosis for multicentric Castleman disease is more variable and depends on several factors, including the specific subtype, how quickly treatment is started, and how well the disease responds to therapy. The introduction of newer biological medications, particularly those targeting the inflammatory protein interleukin-6, has significantly improved outcomes for many patients. Patients who respond well to siltuximab, the FDA-approved treatment for idiopathic multicentric Castleman disease, tend to have long-term responses and better outcomes.
Some patients with idiopathic multicentric Castleman disease may have asymptomatic periods where they feel relatively well, while others experience more severe symptoms requiring intensive treatment. The most serious form, called iMCD-TAFRO, can be life-threatening if not treated promptly and appropriately, as it involves severe organ dysfunction including kidney problems, low platelet counts, and dangerous fluid accumulation.
Survival Rate
Historically, the five-year overall survival rate for multicentric Castleman disease ranged from 55% to 77%. However, it's important to recognize that these statistics were established before newer treatments became available, and survival rates have likely improved with advances in therapy. The introduction of biological agents that target specific disease mechanisms, such as rituximab for HHV-8-associated multicentric Castleman disease and siltuximab for idiopathic multicentric Castleman disease, has changed the treatment landscape and improved patient outcomes.
For unicentric Castleman disease, survival rates after complete surgical removal of the affected lymph node approach those of the general population, meaning most patients can expect a normal lifespan. Even in cases where the lymph node cannot be completely removed, the prognosis often remains favorable, with partially resected masses sometimes remaining stable and asymptomatic for many years.
